Maternal Health Therapeutics Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Maternal Health Therapeutics Market 

5.1. COVID-19 Landscape: Maternal Health Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Maternal Health Therapeutics Market, By Therapeutic Category

8.1. Maternal Health Therapeutics Market, by Therapeutic Category

8.1.1. Oxytocics & Uterotonics

8.1.1.1. Market Revenue and Forecast

8.1.2. Antihypertensives (Pregnancy-safe)

8.1.2.1. Market Revenue and Forecast

8.1.3. Antibiotics & Anti-infectives

8.1.3.1. Market Revenue and Forecast

8.1.4. Anticoagulants/Antithrombotic

8.1.4.1. Market Revenue and Forecast

8.1.5. Diabetes Management (Insulin & Adjuncts)

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Maternal Health Therapeutics Market, By Indication

9.1. Maternal Health Therapeutics Market, by Indication

9.1.1. Postpartum Haemorrhage (PPH)

9.1.1.1. Market Revenue and Forecast

9.1.2. Hypertensive Disorders of Pregnancy (Preeclampsia/Eclampsia)

9.1.2.1. Market Revenue and Forecast

9.1.3. Gestational Diabetes Mellitus (GDM)

9.1.3.1. Market Revenue and Forecast

9.1.4. Maternal Infections (UTI, sepsis, chorioamnionitis)

9.1.4.1. Market Revenue and Forecast

9.1.5. Maternal Anaemia

9.1.5.1. Market Revenue and Forecast

9.1.6. Thrombosis/VTE Risk Management

9.1.6.1. Market Revenue and Forecast

9.1.7. Other Indications

9.1.7.1. Market Revenue and Forecast

Chapter 10. Global Maternal Health Therapeutics Market, By Route of Administration 

10.1. Maternal Health Therapeutics Market, by Route of Administration

10.1.1. Injectable

10.1.1.1. Market Revenue and Forecast

10.1.2. Oral

10.1.2.1. Market Revenue and Forecast

10.1.3. Other Routes (rectal, transdermal)

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Maternal Health Therapeutics Market, By Distribution Channel 

11.1. Maternal Health Therapeutics Market, by Distribution Channel

11.1.1. Hospital Pharmacie

11.1.1.1. Market Revenue and Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast

11.1.4. Government/Public Health Procurement Programs

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Maternal Health Therapeutics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapeutic Category

12.1.2. Market Revenue and Forecast, by Indication

12.1.3. Market Revenue and Forecast, by Route of Administration

12.1.4. Market Revenue and Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapeutic Category

12.1.5.2. Market Revenue and Forecast, by Indication

12.1.5.3. Market Revenue and Forecast, by Route of Administration

12.1.5.4. Market Revenue and Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapeutic Category

12.1.6.2. Market Revenue and Forecast, by Indication

12.1.6.3. Market Revenue and Forecast, by Route of Administration

12.1.6.4. Market Revenue and Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapeutic Category

12.2.2. Market Revenue and Forecast, by Indication

12.2.3. Market Revenue and Forecast, by Route of Administration

12.2.4. Market Revenue and Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapeutic Category

12.2.5.2. Market Revenue and Forecast, by Indication

12.2.5.3. Market Revenue and Forecast, by Route of Administration

12.2.5.4. Market Revenue and Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapeutic Category

12.2.6.2. Market Revenue and Forecast, by Indication

12.2.6.3. Market Revenue and Forecast, by Route of Administration

12.2.6.4. Market Revenue and Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapeutic Category

12.2.7.2. Market Revenue and Forecast, by Indication

12.2.7.3. Market Revenue and Forecast, by Route of Administration

12.2.7.4. Market Revenue and Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapeutic Category

12.2.8.2. Market Revenue and Forecast, by Indication

12.2.8.3. Market Revenue and Forecast, by Route of Administration

12.2.8.4. Market Revenue and Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapeutic Category

12.3.2. Market Revenue and Forecast, by Indication

12.3.3. Market Revenue and Forecast, by Route of Administration

12.3.4. Market Revenue and Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapeutic Category

12.3.5.2. Market Revenue and Forecast, by Indication

12.3.5.3. Market Revenue and Forecast, by Route of Administration

12.3.5.4. Market Revenue and Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapeutic Category

12.3.6.2. Market Revenue and Forecast, by Indication

12.3.6.3. Market Revenue and Forecast, by Route of Administration

12.3.6.4. Market Revenue and Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapeutic Category

12.3.7.2. Market Revenue and Forecast, by Indication

12.3.7.3. Market Revenue and Forecast, by Route of Administration

12.3.7.4. Market Revenue and Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapeutic Category

12.3.8.2. Market Revenue and Forecast, by Indication

12.3.8.3. Market Revenue and Forecast, by Route of Administration

12.3.8.4. Market Revenue and Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapeutic Category

12.4.2. Market Revenue and Forecast, by Indication

12.4.3. Market Revenue and Forecast, by Route of Administration

12.4.4. Market Revenue and Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapeutic Category

12.4.5.2. Market Revenue and Forecast, by Indication

12.4.5.3. Market Revenue and Forecast, by Route of Administration

12.4.5.4. Market Revenue and Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapeutic Category

12.4.6.2. Market Revenue and Forecast, by Indication

12.4.6.3. Market Revenue and Forecast, by Route of Administration

12.4.6.4. Market Revenue and Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapeutic Category

12.4.7.2. Market Revenue and Forecast, by Indication

12.4.7.3. Market Revenue and Forecast, by Route of Administration

12.4.7.4. Market Revenue and Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapeutic Category

12.4.8.2. Market Revenue and Forecast, by Indication

12.4.8.3. Market Revenue and Forecast, by Route of Administration

12.4.8.4. Market Revenue and Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapeutic Category

12.5.2. Market Revenue and Forecast, by Indication

12.5.3. Market Revenue and Forecast, by Route of Administration

12.5.4. Market Revenue and Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapeutic Category

12.5.5.2. Market Revenue and Forecast, by Indication

12.5.5.3. Market Revenue and Forecast, by Route of Administration

12.5.5.4. Market Revenue and Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapeutic Category

12.5.6.2. Market Revenue and Forecast, by Indication

12.5.6.3. Market Revenue and Forecast, by Route of Administration

12.5.6.4. Market Revenue and Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Novartis AG (Switzerland)

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Johnson & Johnson (U.S.)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Shionogi & Co., Ltd.  (Japan)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Bayer AG (Germany)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Bristol-Myers Squibb Company (U.S.)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Biogen (U.S.)

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer Inc. (U.S)

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Merck & Co., Inc. (U.S.)

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Abbott

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Abbott

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms